BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30261554)

  • 1. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
    Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
    Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
    Thomas H; Boddy AV; English MW; Hobson R; Imeson J; Lewis I; Morland B; Pearson AD; Pinkerton R; Price L; Stevens M; Newell DR
    J Clin Oncol; 2000 Nov; 18(21):3614-21. PubMed ID: 11054434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2005 Mar; 59(3):314-24. PubMed ID: 15752378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
    Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
    Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
    Adamson PC; Veal GJ; Womer RB; Meany HJ; Bernhardt MB; Frazier AL; Balis FM
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27672. PubMed ID: 30767382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
    Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
    Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
    Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
    Nath CE; Shaw PJ; Montgomery K; Earl JW
    Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
    Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
    Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
    Chinnaswamy G; Cole M; Boddy AV; Keir M; Price L; Parry A; English M; Veal GJ;
    Br J Cancer; 2008 Sep; 99(6):894-9. PubMed ID: 18781149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
    Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
    J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma.
    Shepherd ST; Gillen G; Morrison P; Forte C; Macpherson IR; White JD; Mark PB
    Eur J Cancer; 2014 Mar; 50(5):944-52. PubMed ID: 24445148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
    White-Koning M; Osborne C; Paci A; Boddy AV; Chatelut E; Veal GJ
    Eur J Cancer; 2018 Mar; 91():56-67. PubMed ID: 29335155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
    Morrow A; Garland C; Yang F; De Luna M; Herrington JD
    J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
    Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
    Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
    Veal GJ; Cole M; Errington J; Pearson AD; Gerrard M; Whyman G; Ellershaw C; Boddy AV
    Cancer Chemother Pharmacol; 2010 May; 65(6):1057-66. PubMed ID: 19701749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.